The investigational articulated analysis FTY720 (fingolimod) continues to illustrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to untrodden clinical data presented today from an non-stop Slant gradually introduce II turn over extension1.
Results showed that 73% of patients who began the study on FTY720 5 mg remained immune from from relapses after three years, and 68% of those who began the deliberate over on FTY720 1.25 mg remained relapse-free1. The figures after two years of treatment were 77% and 75% respectively3. On the basis of comparable efficacy and a more safety profile, all patients enjoy been transferred to FTY720 1.25 mg in the study extension.
The 36-month data also showed an ordinary annualized weaken chew out of 0.201, equivalent to joke deterioration in five years, while 89% of patients were independent of the effectual brain lesions characteristic of MS as dignified by magnetic resonance imaging (MRI)1 three years after starting treatment.
The results were presented at the 60th annual meet of the American Academy of Neurology (AAN) in Chicago, USA.
“These new data demonstrate the stirring aptitude as a remedy for FTY720 to reduce retrogressing rates in MS patients with a accessible once-continuously pill,” said Professor Giancarlo Comi, Professor of Neurology at the University Vita-Salute San Raffaele in Milan, Italy. “An remarkable oral treatment would be a significant breakthrough in the management of MS. That is why these results are encouraging - because we are seeing substantial benefits of FTY720 maintained over heretofore in this clinical trial.”
FTY720 is a best-seller, once-commonplace, spoken treatment in worldwide Phase III clinical happening
because the treatment of relapsing-remitting MS, the genus of the disease that affects
approximately 85% of people diagnosed with MS4.
More than 2.5 million people worldwide are affected by MS2, the most proletarian nontraumatic
cause of neurological disability in young people5. Regulatory filings in the service of FTY720
are expected in the US and EU before the bring to an end of 2009.
“The FTY720 Phase III program is the largest conducted in MS to outmoded, and demonstrates
our long-appellation commitment to the field of MS analysis,” said Trevor Mundel, MD, Head of
Global Development Functions at Novartis Pharma AG. “It is especially encouraging to see
that FTY720 continues to march sustained efficacy by helping the best part of
patients to stay put unoccupied of relapses as the study progresses.”
FTY720 has the possible to be the first in a new class of therapies because of MS that act on
inflammation by modulating sphingosine-1-phosphate receptors (S1P-R), reducing the
covey of inflammatory immune cells, called lymphocytes, from reaching the thought. In
addition, FTY720 reaches the brain and S1P-Rs are award on central fretful system
(CNS) combination, so FTY720 may bring into the world a usher helpful effect on MS within the CNS. This
additional potential mechanism of action is supported by hip preclinical data being
presented at AAN6,7.
The Side II investigate presented at AAN began with a six-month placebo-controlled moment in
which 281 patients with relapsing MS received placebo, FTY720 1.25 mg or FTY720 5 mg
once-daily. This was followed by a long-locution extension in which all patients took FTY720.
At the end of three years, 173 patients were in the extension, which is however ongoing. The
study has been conducted in Canada and 10 European countries.
Results from the six-month placebo-controlled trial showed that FTY720 reduced fall back
rates by more than 50% compared to placebo5. Current first-line therapies throughout MS reduced
relapse rates by 30-35% on as a rule in two-year studies5.
Amidst patients at first on placebo who converted to lively therapy in the extension,
51% were free of relapses at three years1. The chassis at two years was 57%3.
FTY720 has been in the main well tolerated throughout the three years of the Phase II study
and its extension, with the most unexceptional adverse events being nasopharyngitis, headache,
fatigue and influenza1. Increases in alanine aminotransferase (liver enzymes) were observed
in 16% of patients. Dermatological screening of patients was implemented in the scope
after a little number of cases of localized skin malignancies were reported.
Novartis continues to study FTY720 in an ongoing, blinded Put a stop to III clinical trial
program. This program includes comprehensive monitoring that when one pleases further assess and
characterize the shelter chart of FTY720.
MS is caused by the destruction of myelin, which helps neurons tote electrical signals in
the brain8. The disease causes problems with muscle control and brawn, vision, counterbalance,
sensation and mental function8. MS typically presents in relapsing forms involving exquisite
self-limiting attacks of neurological dysfunction (or “relapses”) followed by complete or
partial restoration of functions.
Disclaimer
The set release contains brazen-looking statements that can be identified by
jargon such as “planned”, “potential”, “would”, “encouraging”, “expected”,
“commitment”, “may”, “continues”, “will”, or similar expressions, or by explicit or
implied discussions regarding developing time to come regulatory filings or marketing approvals recompense
FTY720 or regarding imminent future revenues from FTY720. Such forward-looking
statements reflect the current views of the Partnership regarding future events, and involve
known and unknown risks, uncertainties and other factors that may producer actual results
with FTY720 to be essentially distinct from any future results, performance or FTY720 will be submitted to regulatory authorities for the duration of put one’s imprimatur on, or settle upon be approved for
sale in any market. Nor can there be any obligation that FTY720 will obtain any
specific levels of revenue in the future. In particular, management’s expectations
anent FTY720 could be acted upon by, middle other things, unexpected clinical hardship
results, including unexpected modish clinical data and unexpected additional study of
existing clinical data; unexpected regulatory actions or delays or government regulation
generally; the company’s gifts to obtain or maintain manifest or other proprietary
intellectual property protection; contention in combined; government, industriousness and general
public pricing pressures, and other risks and factors referred to in Novartis AG’s current
Form 20-F on file with the US Securities and Stock market Commission. Should song or more
of these risks or uncertainties materialize, or should underlying assumptions prove
specious, true to life results may fluctuate materially from those anticipated, believed, estimated or
expected. Novartis is providing the news in this correspondents remission as of this date and does
not undertake any obligation to update any forward-looking statements contained in this
press disenthral as a result of new information, approaching events or in another situation.
Not far from Novartis
Novartis AG provides healthcare solutions that address the evolving needs of patients and
societies. Focused solely on evolvement areas in healthcare, Novartis offers a diversified
portfolio to superior meet these needs: innovative medicines, get-saving generic
pharmaceuticals, impediment vaccines and diagnostic tools, and consumer health products.
Novartis is the only company with unsurpassed positions in these areas. In 2007, the Group’s
continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1
billion and net takings of USD 6.5 billion. Generally USD 6.4 billion was invested in
R&D activities throughout the Crowd. Headquartered in Basel, Switzerland, Novartis
Group companies utilize approximately 98,200 full-straightaway associates and manipulate in over
140 countries around the world. Seeking more advice, amuse visit
http://www.novartis.com.
References
1. Comi G et al. Oral FTY720 (fingolimod) in patients with relapsing multiple sclerosis. 3-year extension
shows sustained indecent deteriorate fee and MRI activity. Abstract presented at 60th annual meeting of American
Academy of Neurology, Chicago 12-19 April 2008.
2. National Multiple Sclerosis Society website. http://www.nationalmssociety.org/about-multiplesclerosis/
who-gets-ms/index.aspx. Accessed March 11, 2008.
3. Kappos L. et al. Uttered fingolimod (FTY720) in relapsing MS: 24-month results of the Inject II read.
ECTRIMS 2006.
4. National Multiple Sclerosis Brotherhood website. http://www.nationalmssociety.org/about-multiplesclerosis/
what-is-ms/index.aspx. Accessed March 11, 2008.
5. Kappos L et al. Said Fingolimod (FTY720) for Relapsing Multiple Sclerosis. N Engl J Med 2006;355, p.
1130.
6. Barske C et al. FTY720 (Fingolimod) and S1P-Receptor 1 and 5 specific Agonists Increase the Gang of
Oligodendrocytes in Vitro. Conceptual presented at 60th annual meeting of American Academy of
Neurology, Chicago 12-19 April 2008.
7. Schubart A et al. FTY720 suppresses non-stop EAE and promotes a remyelinating ecosystem preventing
axonal degeneration within the CNS. Abstract presented at 60th annual congregation of American Academy of
Neurology, Chicago 12-19 April 2008.
8. Nationalistic Multiple Sclerosis Society website. http://www.nationalmssociety.org/about-multiplesclerosis/
symptoms/index.aspx. Accessed March 11, 2008.